Development of a human immunodeficiency virus type 1 (HIV-1) vaccine remains a global priority. Only 4 vaccine concepts have completed evaluation in field trials [1] [2] [3] [4] [5] , and to date only 1 study has shown a reduction in the risk of HIV-1 infection among vaccine recipients [4] . Vaccine-elicited T-cell responses have not been effective in preventing HIV-1 infection or reducing viremia [1, 3, 5] , perhaps because they targeted an insufficient number of epitopes [6] or because they targeted highly variable regions of the viral genome [7] . However, vaccine-elicited HIV-1-specific T-cell responses have been found to exert selective pressure on infecting viruses [8] , and an increased breadth of vaccine-induced Gag-specific T cells has been associated with a reduced viral load following infection [9] . Furthermore, in chronic HIV-1 infection, control of viremia correlates with the breadth of CD8 + T-cell recognition of specific Gag epitopes [10] [11] [12] .
Mosaic immunogens are in silico-derived, full-length recombinant proteins optimized to maximize potential T-cell epitopes and are designed to allow natural expression and antigen processing and presentation [13] . Studies of complementary bivalent or trivalent mosaic HIV-1 immunogens in macaques have shown that mosaic sequences increase the breadth and depth of cellular immune responses, compared with either consensus or natural sequences [14, 15] . This increased magnitude and quality of cellular immune responses could potentially improve the coverage of circulating viruses and help control viremia by preventing the in vivo evolution of variant escape viruses. Recent evidence from the nonhuman primate/simian immunodeficiency virus (SIV) model supports the association of an increased magnitude and breadth of vaccine-elicited cellular responses with viremic control, using conventional SIV immunogens [16] . Furthermore, macaques vaccinated with HIV mosaic Gag/Pol/Env were able to inhibit acquisition of infection in a macaque SIV/HIV (SHIV) heterologous challenge study, and the vaccinated animals had increased survival rates and reduced viral loads [17] .
In this study, we report the first-in-human safety and immunogenicity evaluation of a mosaic HIV-1 vaccine that uses modified vaccinia Ankara (MVA) as a delivery system and evaluate the capacity of this novel immunogen to induce cross-clade immune responses.
METHODS

Vaccine
The vaccine used in this study was an MVA-vectored HIV-1 bivalent mosaic immunogen vaccine (MVA.mos1 and MVA. mos2; MVA Mosaic), which delivered 2 different but complementary HIV-1 gag/pol/env inserts [14] and was administered at a total dose of 1✕10 8 plaque-forming units. The MVA mosaic vaccine was provided by the US Military HIV Research Program and Janssen was responsible for the investigational new drug application. The placebo was 0.9% sodium chloride, USP.
Participants and Study Design
This study was a single center, randomized, double-blinded, placebo-controlled trial to evaluate safety and immunogenicity of a single dose regimen of MVA Mosaic vaccine administered at a total dose of 1✕10 8 plaque-forming units/mL at weeks 0 and 12, an interval that has been used in other HIV-1 vaccine studies [18, 19] . Study subjects were healthy volunteers at low risk for acquiring HIV, based on standard criteria [20] . The protocol was approved by the institutional review board and biosafety committee, and written informed consent was obtained from each subject. The study was registered at ClinicalTrials.gov (NCT02218125).
Two groups of subjects were enrolled: those who were naive to a prior HIV-1 vaccine (n = 15) and those who had received 2 or 3 doses of a prototype HIV-1 vaccine (Ad26.ENVA.01) containing only an EnvA insert (clinical trials registration NCT00618605) [21] between 4 and 6 years earlier (n = 10). Within each group, subjects were randomized to receive MVA Mosaic vaccine or placebo at a 4:1 ratio. Therefore, among naive subjects, 12 received MVA Mosaic vaccine (group 1), and 3 received placebo; and among past recipients of Ad26.ENVA.01, 8 received MVA Mosaic vaccine (group 2), and 2 received placebo. Injections were given on days 0 and 84. All vaccines were given by needle and syringe (0.5 mL) in the deltoid muscle, preferentially in the subjects' nondominant arm. Systematic safety assessments were conducted and are described in the Supplementary Materials.
Immunogenicity Studies
Immunogenicity assessments were performed on samples collected on days 0, 14, 28, 84, 98, 112, 168, 270, and 365. All immunogenicity assays were performed in a blinded fashion according to good clinical laboratory practices and are described in detail in the Supplementary Materials. Interferon γ (IFN-γ) enzyme-linked immunospot (ELISPOT) assays were performed to assess HIV-specific cellular immune responses, using pools of overlapping peptides [22] derived from Gag, Pol, and Env and corresponding to the Mosaic 1 and Mosaic 2 sequences, as well as the potential T-cell epitope Gag/Pol/Env sets [23] and EnvA. Intracellular cytokine staining for IFN-γ and interleukin 2 (IL-2) was performed as described elsewhere [24, 25] , following stimulation with peptide pools corresponding to Gag (Mos1 and Mos2) and Env (potential T-cell epitope). Direct enzymelinked immunosorbent assays (ELISAs) were performed with sera to assess HIV-specific binding antibodies against clade A (92UG037), clade B (UK7LN), clade C (C97ZA.012), and Mos1 gp140 trimers [22] . The HIV-1 Env-specific neutralizing antibody titer was quantified by the TZM-bl assay [26] . Antibodies binding to Env V2 and V3 loops were determined by surface plasmon resonance in quadruplicate as described previously [27] , with modifications. Antibody-dependent cellular phagocytosis was measured with beads coated with Env from HIV-1 clades A, B, and C, using the THP-1 phagocytosis assay as described previously [28, 29] . Luciferase-based MVA neutralization assays were performed to assess vector-specific neutralizing antibodies as previously described [30] . Ad26-specific neutralizing antibodies were quantified in participants who had previously received Ad26.ENVA.01, using a luciferase-based assay as described elsewhere [31] .
Criteria for positive MVA neutralizing antibody responses were titers of >20 and those for Env ELISA responses were titers of ≥100; antibody responses below the lower limit of quantitation of the assay were imputed to half the numeric value of the lower limit of quantitation. Criteria for ELISPOT assay positivity were ≥55 spot-forming cells (SFCs) per million peripheral blood mononuclear cells (PBMCs) and at least 3 times greater than the background value; ELISPOT responses that were <10 following subtraction of medium-only responses were considered baseline values and imputed as a response of 10.
Statistical Methods
All analyses are based on the intent-to-treat principle; all subjects are evaluated as members of the group to which they were randomized. Summaries of responses are presented as median titers, for the MVA neutralizing antibody test and HIV-1 ELISA data, and as median numbers of SFCs, for the HIV-1 ELISPOT data. Differences in proportions were tested with 2-sided Fisher exact tests. Kruskal-Wallis nonparametric analysis of variance was used to test for differences among the groups. When a significant overall difference in the result yielded by the Kruskal-Wallis test was identified at a given time point, pairwise tests of all possible treatment pairs were performed using the Mann-Whitney-Wilcoxon nonparametric test. Paired data were assessed using the Wilcoxon signed rank test. Tests with a 2-sided P value of <.05 were considered statistically significant. As this was a phase 1 study, no adjustments were made for multiple comparisons.
RESULTS
Subject Characteristics
Of the 25 subjects enrolled (Supplementary Figure 1) , the sex of 20 (80%) was female, the median age was 24 years (range, 19-49 years), and the race/ethnicity of 1 (4%) was African American, of 4 (16%) was Asian, and of 19 (76%) was non-Hispanic white. Overall retention was 99% (296 of 300 planned visits completed), and 50 of 50 planned vaccinations (100%) were given.
Safety and Tolerability
The MVA Mosaic vaccine was safe and generally very well tolerated ( Figure 1 ). Two serious adverse events (SAEs) occurred during the study, and neither was deemed related to the vaccine. Three subjects had a greater than moderately severe AE, all of which were considered unrelated to vaccination: dental infection, an SAE, occurred on day 355 in the placebo group; thyroid cancer, an SAE, was detected on day 166 in group 1; and urinary tract infection, an AE, was detected on day 80 in group 1. No significant abnormal laboratory findings were observed, and no cardiac events [32] were noted. All grade ≥2 unsolicited AEs were deemed probably not or not related to study vaccination.
The mild-to-moderate systemic reactogenicity pattern noted with the first dose generally occurred within the first 24-48 hours following vaccination and typically resolved spontaneously within another 1-2 days. The mild-to-moderate local reactogenicity symptoms occurred within 1-2 days of vaccination and resolved over 4-7 days. There were no significant differences in reactogenicity among the groups. Seventeen of 20 vaccinees had vaccine-induced seropositivity [33] when tested at the end-of-study visit by means of commonly used HIV diagnostic tests.
HIV-1-Specific Cellular Immune Responses
Five subjects from group 2 had detectable IFN-γ ELISPOT responses to at least 1 Env protein pool at baseline, likely reflecting their exposure to Ad26.ENVA.01. Figure 2 shows the kinetics of the responses by vaccination group. Env-specific responses were detected in 8 group 1 subjects after the first vaccine dose and in 10 after the second dose. By comparison, all 8 group 2 subjects had detectable responses to at least 1 Env peptide pool after the first injection ( Figure 2 and Supplementary  Figure 2 ). Most group 2 subjects had a further increase in the magnitude of ELISPOT responses to the Env pools after the second inoculation. Median ELISPOT responses on days 0, 14, 98, and 365 to potential T-cell epitope Env peptides ( Figure 2A ) were 11, 99, 207, and 120 SFCs/10 6 PBMCs, respectively, in group 1 subjects and 74, 611, 647, and 475 SFCs/10 6 PBMCs, respectively, in group 2 subjects (P = .0008 and P = .0028 for the difference between groups on days 14 and 98, respectively). These responses were significantly different from the baseline responses in group 1 subjects (P < .003 at all time points) and group 2 subjects (P < .016 at all time points). Median responses to EnvA peptides (Supplementary Figure 2A) were 10, 40, 77, and 69 SFCs/10 6 PBMCs, respectively, among group 1 subjects and 36, 503, 452, and 375 SFCs/10 6 PBMCs, respectively, among group 2 subjects (P < .0001 and P = .0001 for days 14 and 98, respectively) and were significantly different than baseline values at all time points (P < .014 and P < .016 for group 1 and group 2 subjects, respectively). Among placebo recipients, ELISPOT responses against potential T-cell epitope Env or EnvA peptide pools were not significantly different from baseline values at any time point. Compared with placebo recipients, ELISPOT responses were higher among group 1 subjects at all postvaccination time points until day 365 (P < .04) and higher among group 2 subjects at all postvaccination time points (P < .007). Baseline responses to any Gag or Pol peptide pool did not differ among the groups and remained at background levels in placebo recipients throughout the study ( Figure 2B and 2C and Supplementary Figure 3) . After the first injection, rates of ELISPOT responses to the potential T-cell epitope Gag pool ( Figure 2B ) did not differ between group 1 and group 2. After the second injection of MVA Mosaic, 7 subjects in group 1 and 4 subjects in group 2 had responses to at least 1 Gag pool. Median ELISPOT responses on days 0, 14, 98, and 365 to potential T-cell epitope Gag peptides were 24, 46, 70, and 77 SFCs/10 6 PBMCs, respectively, among group 1 subjects and 30, 40, 54, and 75 SFCs/10 6 PBMCs, respectively, among group 2 subjects (P = not significant at all time points, compared with baseline). Compared with Gag-specific ELISPOT responses among placebo recipients, those among group 1 subjects were only significantly different at day 98 (P = .0076), and those among group 2 subjects were not significantly different at any time point.
Three group 1 subjects and 3 group 2 subjects had responses to at least 1 Pol pool after the first injection, while 7 group 1 subjects and 5 group 2 subjects had responses to one of the Pol pools following the second vaccination ( Figure 2C and Supplementary  Figure 3) . After the first injection, rates of ELISPOT responses to the potential T-cell epitope Pol pool did not differ between group 1 and group 2. Median ELISPOT responses on days 0, 14, 98, and 365 to Pol peptides ( Figure 2C were 27, 33, 77, and 45 SFCs/10 6 PBMCs, respectively, among group 1 subjects and 33, 28, 59, and 49 SFCs/10 6 PBMCs, respectively, among group 2 subjects (P = not significant at all time points, compared with baseline). Compared with Pol-specific ELISPOT responses among placebo recipients, responses were significantly different only on day 98 among group 1 subjects (P = .0206) and only on day 168 among group 2 subjects (P = .0328).
Two weeks after the second vaccination, modest CD4 + T-cell responses to the potential T-cell epitope Env peptide pool were detected by intracellular cytokine staining, without clear differences between group 1 and group 2 ( Figure 3A) . Modest CD8 + T-cell responses were detected to Env as well, although predominantly in group 2 ( Figure 3B) . A minority of subjects had detectable CD4 + or CD8 + T-cell responses to Gag (Mos1 or Mos2) pools ( Figure 3C-F) . Individual cytokine responses are shown in Supplementary Figures 5 (for IL-2) and 6 (for IFN-γ) .
Taken together, these data show that MVA Mosaic consistently induced HIV-specific cellular immune responses against Env peptides and that these responses could be maintained for 1 year. Responses against Gag and Pol were modest but were detectable in some vaccinees.
HIV-1 Env-Specific Antibody Responses
All subjects in group 1 had negative results of EnvA-specific ELISA binding antibody tests at baseline, and results for all naive subjects in the placebo group remained negative throughout the study. Of subjects in group 2, only 1 had detectable ELISA responses to EnvA at baseline. No subjects had detectable responses to EnvB, EnvC, or Mos1 gp140 at baseline. Figure 4 shows the kinetics of the binding antibody responses by vaccination group. After the first injection of MVA Mosaic, 5 subjects (63%) in group 2 had positive responses to at least 1 Env antigen assayed, while all group 1 subjects remained seronegative (P = .0036). At day 112, after the second injection, 10 group 1 subjects (88%) had positive responses to at least 1 Env antigen; response rates and titers were highest against the clade B antigen. Among group 2 subjects, 7 (88%) responded to at least 2 Env antigens, with an increase in titer against all 4 antigens assayed.
At days 0, 28, 112, and 365 median clade A (92UG037.9) ELISA titers were 25, 25, 225, and 25, respectively, in group 1 and 25, 150, 225, and 75, respectively, in group 2; median clade B (UK7LN) ELISA titers were 25, 25, 450, and 50, respectively, in group 1 and 25, 225, 450, and 75, respectively, in group 2; median clade C (C97ZA.012) ELISA titers were 25, 25, 150, and 13, respectively, in group 1 and 25, 75, 225, and 25, respectively, in group 2; and median Mos1 titers were 25, 25, 450, and 50, respectively, in group 1 and 25, 150, 450, and 75, respectively, in group 2. The responses in group 2 were highly statistically significant as compared to those in group 1 at day 28 (P < .0008) but not at days 112 or 365 for all 4 Env antigens assayed.
All subjects had negative results of neutralizing antibody tests at baseline (Figure 5) , and results for all subjects in the placebo group remained negative throughout the study. After both injections of MVA Mosaic, 9 group 1 subjects had neutralizing antibody responses to at least 1 tier 1 virus assayed at day 112, while 5 group 2 subjects had neutralizing antibody responses (P = not significant). Median responses did not differ between the groups.
Because the binding antibody titer against the V1V2 loop of Env was found to be a correlate of protection in the Thai RV144 trial [34] , we analyzed binding antibodies against several cyclic peptide constructs, using surface plasmon resonance ( Figure 6) . After a single dose of MVA Mosaic, antibody levels did not significantly rise in either group 1 or group 2 subjects when assayed with cyclic V2 or V3 loop peptides derived from a clade AE isolate (92TH023). However, modest increases were detected after the second vaccination, without differences between groups.
We also assessed functional nonneutralizing antibody responses by assaying antibody-dependent cellular phagocytosis ( Figure 7) . After 2 doses of MVA Mosaic, subjects in group 1 and group 2 had significantly increased antibody-dependent cellular phagocytosis scores, compared with baseline, when assayed with a clade A Env (P = .0269 and P = .0078, respectively), a clade B Env (P = .0210 and P = .0078, respectively), and 1 of 2 clade C Envs (P = .0342 and P = .0078, respectively, for 1086C and P = not significant in either group for ZA). These data show that MVA Mosaic consistently induced Envspecific binding antibody responses and that these responses were cross-reactive against Env proteins derived from at least 3 clades.
Antivector neutralizing antibody responses are presented in the Supplementary Materials.
DISCUSSION
These data provide the first assessment of a mosaic immunogen in humans. The novel recombinant MVA mosaic vaccine candidate was generally safe, well tolerated, and immunogenic in this first-in-human evaluation of the mosaic immunogen concept. In group 1, both cellular and humoral cross-clade immune responses were elicited after 1 or 2 vaccinations in all participants. Env-specific responses were induced after a single immunization in nearly all group 2 subjects. All group 2 groups developed both vector-specific and insert-specific humoral immune responses that generally persisted for 1 year. These findings are consistent with data from a nonhuman primate model in which MVA mosaic vectors elicited humoral and cellular responses and provided partial protection against SHIV challenges in a heterologous prime-boost vaccine regimen [17] .
HIV-specific T-cell responses were elicited in most vaccinees, but Env-specific responses were higher in frequency and magnitude than Gag-or Pol-specific responses. Group 2 subjects had an amnestic response to Env after receipt of vaccine, in terms of both humoral and cellular immune responses. The recall immune responses appeared more rapidly (after a single vaccination) and reached a greater magnitude as compared to responses in group 1. In group 1, the increased immune response detected after the second vaccination is consistent with responses seen after receipt of other MVA-vectored HIV-1 vaccines [35, 36] . Group 2 subjects appeared to have slightly lower rates and magnitudes of responses to Gag and Pol, suggesting that recall responses dominate de novo responses, a phenomenon termed "original antigenic sin" [37] . Env-specific binding antibody responses detected by ELISA were elicited in nearly all subjects after the first immunization to the homologous antigen (Mos1) and to at least 3 clades (A, B, and C), and they persisted 1 year after the first vaccination.
Interestingly, these responses also suggested an amnestic pattern among group 2 subjects (for whom responses rapidly appeared after the first vaccination and were high in magnitude), compared with group 1 subjects (for whom no responses were detected until after the second vaccination).
Several recombinant MVA-HIV vaccine vectors have completed phase 1 and phase 2 trials in recent years [38] . Overall, these vaccines have been well tolerated, with no vaccine-related SAEs identified [35, 36, 39] . In one study, 69% of MVA-HIV vaccinees developed HIV-specific binding antibodies, but only 43% developed HIV-specific CD4 + T-cell responses, and only 21% developed insert-specific CD8 + T-cell responses [35] . In a more recent study with a different MVA-HIV vaccine, 98% of vaccinees developed Env-specific binding antibodies, while only 43% and 15% of vaccinees developed HIV-specific CD4 + and CD8 + T-cell responses, respectively [40] . These studies suggest that MVA vectors delivering natural HIV-1-derived inserts are immunogenic in humans and may have a role eliciting humoral and CD4 + T-cell responses. Despite the induction of robust MVA vector-specific neutralizing antibody responses, EnvA insert-specific binding antibody responses were increased following a second vaccination with the homologous vector, and we found no evidence that MVA vector-specific neutralizing antibodies inhibited insert-specific cellular or humoral immune responses. Remarkably, in group 2 subjects, Ad26 neutralizing antibodies were detectable at baseline, 4-6 years after their last vaccination in the previous study, and HIV-1-specific immune responses were clearly boosted by MVA mosaic, demonstrating that Ad26 vaccine-induced HIV-1 specific immune responses may be long lived. Furthermore, our results are consistent with findings from studies of other candidate HIV-1 vaccines. Joachim et al found that a substantial proportion of subjects who had received a DNA-prime and MVA-boost heterologous regimen still had detectable immune responses 3 years later; these responses were further boosted by an additional dose of the candidate MVA-HIV vaccine [41] . Similarly, although immune responses to an MVAvectored clade B HIV-1 vaccine were found to have decreased over 4 years, an additional dose also boosted HIV-1-specific immune responses, particularly the antibody response [42] .
These data are the first to demonstrate the safety and immunogenicity of the novel recombinant MVA bivalent mosaic vaccine in humans. Importantly, HIV-specific humoral and cellular immune responses were consistently elicited with minimal reactogenicity. Interestingly, prior receipt of a different HIV-1 vaccine (Ad26.ENVA.01) induced a robust Env-specific immune response after a single MVA mosaic vaccination, compared with the response after 2 vaccinations in group 1. This first-in-human study did not include a direct comparison of mosaic and natural sequence immunogens, in order to first verify the immunogenicity of the synthetic mosaic sequences. The novel MVA mosaic vector and the mosaic immunogen concept warrant additional investigation as a vaccine vector for HIV. Future studies will evaluate whether the breadth or magnitude of cellular and humoral immune responses with mosaic immunogens is greater than that with natural sequence immunogens. Based in part on these data, further development of the bivalent mosaic concept is underway, with additional studies using an Ad26 vector as part of a heterologous prime-boost regimen (NCT02315703, NCT02788045, and NCT02935686) and a proof-of-concept trial (NCT03060629) recently initiated.
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